Immune cells engineered to attack deadly brain tumors enter first human test
NCT ID NCT05168423
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 33 times
Summary
This early-phase study tests whether specially engineered immune cells (CART-EGFR-IL13Ra2) are safe and feasible for people with a recurrent, aggressive brain cancer called glioblastoma. About 67 adults whose tumors have returned after standard treatment will receive their own modified cells. The main goal is to check for side effects and determine the best dose, not yet to prove the treatment works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.